Assignee
IMMUNOMET THERAPEUTICS INC
US·12 granted patents·4 pending applications·25 citations·filing 2014–2023
Top patents by PatentIndex Score
16 records- 0186US9539238B2Pharmaceutical composition comprising a biguanide derivative as an active ingredient for preventing or treating glioblastomaIMMUNOMET THERAPEUTICS INC·Filed 2016·Granted Jan 10, 2017·5 cites·7 claims
- 0285US9464042B2Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredientIMMUNOMET THERAPEUTICS INC·Filed 2015·Granted Oct 11, 2016·4 cites·3 claims
- 0383US10626085B2Biguanide compound and use thereofIMMUNOMET THERAPEUTICS INC·Filed 2015·Granted Apr 21, 2020·3 cites·7 claims
- 0482US9884821B2N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the sameIMMUNOMET THERAPEUTICS INC·Filed 2014·Granted Feb 6, 2018·3 cites·12 claims
- 0581US10252996B2N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the sameIMMUNOMET THERAPEUTICS INC·Filed 2017·Granted Apr 9, 2019·2 cites·5 claims
- 0678US10058558B2Pharmaceutical composition comprising N1-cyclic amine-N5-substituted biguanide derivatives as an ingredient for preventing or treating fibrosisIMMUNOMET THERAPEUTICS INC·Filed 2014·Granted Aug 28, 2018·3 cites·10 claims
- 0774US10590081B2Guanidine compounds and use thereofIMMUNOMET THERAPEUTICS INC·Filed 2015·Granted Mar 17, 2020·2 cites·5 claims
- 0873US10221190B2Biguanide compounds and use thereofIMMUNOMET THERAPEUTICS INC·Filed 2014·Granted Mar 5, 2019·2 cites·4 claims
- 0973US9993446B2Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredientIMMUNOMET THERAPEUTICS INC·Filed 2016·Granted Jun 12, 2018·1 cites·7 claims
- 1063US10376480B2Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredientIMMUNOMET THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·0 cites·6 claims
- 1160US2025170096A1Oxphos inhibitors for use in treating cancerIMMUNOMET THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1260US2023000820A1Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereofIMMUNOMET THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1359US11572341B2Biguanide compound and use thereofIMMUNOMET THERAPEUTICS INC·Filed 2020·Granted Feb 7, 2023·0 cites·5 claims
- 1456US2019144464A1Biguanide compounds and use thereofIMMUNOMET THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1541US11465989B2Guanidine compounds and use thereofIMMUNOMET THERAPEUTICS INC·Filed 2015·Granted Oct 11, 2022·0 cites·6 claims
- 1637US2017305861A1Heteroaryl compounds comprising nitrogen and use thereofIMMUNOMET THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →